Generating functionally stable and antigen-specific T <sub>reg</sub> cells from effector T cells for cell therapy of inflammatory diseases

One strategy for antigen-specific immunosuppression is to convert antigen-specific conventional T (T<sub>conv</sub>) cells into Foxp3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells that are as stably suppressive as naturally occurring T<sub>reg</sub> (nT<sub>reg</sub>) cells. To achieve the conversion in vitro for mice and humans, we induced high Foxp3 expression in antigen- and interleukin-2 (IL-2)-stimulated T<sub>conv</sub> cells by CDK8/19 inhibition. We further established T<sub>reg</sub> cell-specific epigenetic changes by depriving CD28 costimulation during in vitro T<sub>reg</sub> cell induction to specifically promote the expression of T<sub>reg</sub> cell signature genes, especially <i>Foxp3</i>. Repeating this process, with intermittent resting cultures containing IL-2 only, enabled efficient conversion of naïve as well as effector/memory CD4<sup>+</sup> T<sub>conv</sub> cells, including T helper 1 (T<sub>H</sub>1), T<sub>H</sub>2, and T<sub>H</sub>17 cells, into Foxp3<sup>+</sup> T<sub>reg</sub> cells. These induced T<sub>reg</sub> (iT<sub>reg</sub>) cells were similar to nT<sub>reg</sub> cells in transcription and epigenetic modification and were functionally and phenotypically stable in vivo. Moreover, they effectively suppressed inflammatory bowel disease and graft-versus-host disease in mouse models. Adoptive cell therapy with such effector/memory T<sub>conv</sub> cell-derived, functionally stable, iT<sub>reg</sub> cells may represent a strategy to achieve antigen- and disease-specific treatment of immunological diseases.

Authors

Institutions

Publication Details

Journal
Science Translational Medicine
Published
2025-10-22
DOI
https://doi.org/10.1126/scitranslmed.adr6049
Citations
10
Primary Topic
T-cell and B-cell Immunology
Type
article
Field-Weighted Citation Impact
7.97
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Generating functionally stable and antigen-specific T reg cells from effector T cells for cell therapy of inflammatory diseases

Atsushi Sugimoto, Ryoji Kawakami, Shimon Sakaguchi, Masaya Arai et al.
10 citations
Science Translational Medicine
T-cell and B-cell Immunology
7.97
article

Generating functionally stable and antigen-specific T reg cells from effector T cells for cell therapy of inflammatory diseases

Atsushi Sugimoto, Ryoji Kawakami, Shimon Sakaguchi, Masaya Arai, Norihisa Mikami
article en
10 citations

Abstract

One strategy for antigen-specific immunosuppression is to convert antigen-specific conventional T (T<sub>conv</sub>) cells into Foxp3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells that are as stably suppressive as naturally occurring T<sub>reg</sub> (nT<sub>reg</sub>) cells. To achieve the conversion in vitro for mice and humans, we induced high Foxp3 expression in antigen- and interleukin-2 (IL-2)-stimulated T<sub>conv</sub> cells by CDK8/19 inhibition. We further established T<sub>reg</sub> cell-specific epigenetic changes by depriving CD28 costimulation during in vitro T<sub>reg</sub> cell induction to specifically promote the expression of T<sub>reg</sub> cell signature genes, especially <i>Foxp3</i>. Repeating this process, with intermittent resting cultures containing IL-2 only, enabled efficient conversion of naïve as well as effector/memory CD4<sup>+</sup> T<sub>conv</sub> cells, including T helper 1 (T<sub>H</sub>1), T<sub>H</sub>2, and T<sub>H</sub>17 cells, into Foxp3<sup>+</sup> T<sub>reg</sub> cells. These induced T<sub>reg</sub> (iT<sub>reg</sub>) cells were similar to nT<sub>reg</sub> cells in transcription and epigenetic modification and were functionally and phenotypically stable in vivo. Moreover, they effectively suppressed inflammatory bowel disease and graft-versus-host disease in mouse models. Adoptive cell therapy with such effector/memory T<sub>conv</sub> cell-derived, functionally stable, iT<sub>reg</sub> cells may represent a strategy to achieve antigen- and disease-specific treatment of immunological diseases.

Science Translational MedicineVol. 17(821)
Kyoto University (JP), The University of Osaka (JP)
Openalex Percentile: Top 2%
T-cell and B-cell Immunology
7.97
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.